Salarius Pharmaceuticals Announces 1-for-15 Reverse Stock Split
HOUSTON, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop ca...
What effect will the split have on key valuation metrics such as EPS, P/E, and price‑to‑sales ratios?
Is the market perceiving the reverse split as a signal of financial distress or a strategic move to improve share perception?
Could the split impact the company’s ability to raise capital in future financing rounds?
12 days ago